Letters: Medical mystery

Image
Business Standard New Delhi
Last Updated : Jul 22 2013 | 9:23 PM IST
This refers to the editorial "Investigate first" (July 18). It is strange that the health ministry has acted in haste to ban the drug pioglitazone, used in the treatment of diabetes, in response to a letter shot off by a Chennai-based doctor V Mohan, who runs a diabetes treatment centre, to the prime minister. The doctor's view that prolonged use of the drug causes bladder cancer has been blindly accepted by the ministry without eliciting expert opinion and taking the issue to the court of other expert doctors for their opinion. The ban order should be revoked till a decision is taken by the Drug Technical Advisory Board that met on July 19. The ministry has ignored the Advisory Board in enforcing the ban, much to the chagrin of regular users of the drug. It is too early to suspect that Mohan had written the letter to promote the sales of sitaglipitin, which is sold in India under the brand Januvia for the treatment of diabetes by MSD Pharmaceuticals that supports a course in Mohan's Academy. An investigation should only confirm or allay the fear expressed by Mohan. In any case, the doctor cannot be punished even if his opinion is found to be wrong.
K V Seetharamaiah Karnataka

Letters can be mailed, faxed or e-mailed to:
The Editor, Business Standard
Nehru House, 4 Bahadur Shah Zafar Marg
New Delhi 110 002
Fax: (011) 23720201
E-mail: letters@bsmail.in
All letters must have a postal address and telephone number
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 22 2013 | 9:01 PM IST

Next Story